Emapalumab (anti-IFNγ)

製品コード：A2041         Batch: A204102

印刷

Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

製品説明

CAS No. 1709815-23-5
Formulation PBS Buffer, PH 7.4
Isotype Human IgG1
Application Emapalumab (anti-IFNγ)
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
Shipping Shipped under low temperature conditions
Purity 98%
Protein concentration 3.6mg/ml
Endotoxin Level ＜1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

IFNγ regulates ferroptosis in KFs by inhibiting the expression of SPOCD1 through DNMT3A [ Cell Death Discov, 2025, 11(1):9] PubMed: 39820341
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma [ Blood Adv, 2024, bloodadvances.2023012522] PubMed: 39058976

人間や獣医の診断であるか治療的な使用のためにでない。